US 11,679,101 B2
Anhydrous compositions of mTOR inhibitors and methods of use
Wesley Harton Kaupinen, Wayne, PA (US); Braham Shroot, Antibes (FR); Simon David Betson, Woking (GB); Charles Rodney Greenaway Evans, Mitcham (GB); and Marc Barry Brown, Watford (GB)
Assigned to PALVELLA THERAPEUTICS, INC., Wayne, PA (US)
Filed by PALVELLA THERAPEUTICS, INC., Wayne, PA (US)
Filed on Apr. 7, 2021, as Appl. No. 17/224,799.
Application 17/224,799 is a continuation of application No. 16/460,125, filed on Jul. 2, 2019, granted, now 11,000,513.
Claims priority of provisional application 62/693,635, filed on Jul. 3, 2018.
Claims priority of provisional application 62/693,283, filed on Jul. 2, 2018.
Prior Publication US 2021/0244713 A1, Aug. 12, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/496 (2006.01); A61K 31/519 (2006.01); A61K 31/47 (2006.01); A61K 31/4523 (2006.01); A61K 31/335 (2006.01); A61P 17/00 (2006.01); A61P 17/04 (2006.01); A61K 31/436 (2006.01); A61K 9/00 (2006.01); A61K 47/34 (2017.01); A61K 47/28 (2006.01); A61K 47/18 (2017.01); A61K 47/24 (2006.01); A61K 47/22 (2006.01); A61K 47/38 (2006.01); A61K 47/14 (2017.01); A61K 47/10 (2017.01); A61K 45/06 (2006.01)
CPC A61K 31/436 (2013.01) [A61K 9/0014 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/18 (2013.01); A61K 47/22 (2013.01); A61K 47/24 (2013.01); A61K 47/28 (2013.01); A61K 47/34 (2013.01); A61K 47/38 (2013.01); A61K 45/06 (2013.01)] 52 Claims
 
1. An anhydrous composition of a mTOR inhibitor comprising:
about 0.1 wt % to about 20 wt % of rapamycin (sirolimus),
about 80 wt % to about 99.9 wt % of a solvent;
about 0.1 wt % to about 5 wt % of a gelling agent;
about 0.001 wt % to about 1 wt % of an antioxidant;
wherein the anhydrous composition is formulated for topical administration.